Cost-Analysis of Relapsing-Remitting Multiple Sclerosis in Italy after the Introduction of New Disease-Modifying Agents

被引：0
|
作者：
Pierluigi Russo
Alessandro Capone
Andrea Paolillo
Francesco Macchia
Federica Ranzato
Gianfranco Costantino
Luca Degli Esposti
Luciano Caprino
机构：
[1] University of Rome “La Sapienza”,Department of Human Physiology and Pharmacology
[2] Economics and Outcome Research,Clicon S.r.l., Health
[3] University of Rome “La Sapienza”,Department of Neurological Sciences
[4] University of Padua,Neurologic Clinic I
[5] Ospedale Civile di Foggia,undefined
来源：
Clinical Drug Investigation | 2004年 / 24卷
关键词：
Multiple Sclerosis; Glatiramer Acetate; Oxybutynin; Tolterodine; Progressive Multiple Sclerosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：409 / 420
页数：11
相关论文
共 50 条
  • [21] Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: A Network Meta-Analysis
    Lucchetta, Rosa C.
    Tonin, Fernanda S.
    Borba, Helena H. L.
    Leonart, Leticia P.
    Ferreira, Vinicius L.
    Bonetti, Aline F.
    Riveros, Bruno S.
    Becker, Jefferson
    Pontarolo, Roberto
    Fernandez-Llimos, Fernando
    Wiens, Astrid
    CNS DRUGS, 2018, 32 (09) : 813 - 826
  • [22] Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics
    Rudick, RA
    ARCHIVES OF NEUROLOGY, 1999, 56 (09) : 1079 - 1084
  • [23] ESTIMATING THE FISCAL CONSEQUENCES OF INVESTMENTS IN DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Mennini, F. S.
    Kotsopoulos, N.
    Connolly, M.
    Gianinazzi, M.
    Pellirone, M.
    Marcellusi, A.
    VALUE IN HEALTH, 2020, 23 : S627 - S628
  • [24] Analysis of the efficiency of combining disease-modifying treatment and phytotherapy in patients with relapsing-remitting multiple sclerosis
    Barnaulov, O. D.
    Osipova, T. V.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 723 - 723
  • [25] New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come
    Nicholas, J.
    Morgan-Followell, B.
    Pitt, D.
    Racke, M. K.
    Boster, A.
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2012, 4 : 81 - 103
  • [26] Cost-utility and cost-effectiveness analysis of disease-modifying drugs of relapsing-remitting multiple sclerosis: a systematic review
    Gallehzan, Nasrin Abulhasanbeigi
    Khosravi, Majid
    Jamebozorgi, Khosro
    Mir, Nazanin
    Jalilian, Habib
    Soleimanpour, Samira
    Hoseini, Saeed
    Rezapour, Aziz
    Eshraghi, Abbas
    HEALTH ECONOMICS REVIEW, 2024, 14 (01)
  • [27] Effects of Cohort Selection on the Results of Cost-Effectiveness Analysis of Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis
    Becker, Russell V., III
    Dembek, Carole
    JOURNAL OF MANAGED CARE PHARMACY, 2011, 17 (05): : 377 - 381
  • [28] The Effects of Disease-Modifying Therapies on Oxidative Stress in Patients With Relapsing-Remitting Multiple Sclerosis
    Topic, Aleksandra
    Vasic, Marija
    Markovic, Bojan
    Milinkovic, Neda
    Dincic, Evica
    CLINICAL NEUROPHARMACOLOGY, 2022, 45 (06) : 157 - 161
  • [29] Olfactory Dysfunction in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Disease-Modifying Therapies
    Wnuk, Marcin
    Drabik, Leszek
    Marona, Monika
    Szaleniec, Joanna
    Bryll, Amira
    Karcz, Paulina
    Kolasinska, Justyna
    Kolasinska, Monika
    Ziekiewicz, Maciej
    Skladzien, Jacek
    Popiela, Tadeusz
    Slowik, Agnieszka
    ENT-EAR NOSE & THROAT JOURNAL, 2022, 101 (10) : 640 - 644
  • [30] Injectable Disease-Modifying Therapy for Relapsing-Remitting Multiple Sclerosis: A Review of Adherence Data
    Caon, Christina
    Saunders, Carol
    Smrtka, Jennifer
    Baxter, Nancy
    Shoemaker, Jennifer
    JOURNAL OF NEUROSCIENCE NURSING, 2010, 42 (05) : S5 - S9
12345